teclistamab
genmab,janssen
['multiplemyeloma', 'teclistamab', 'majestec-1']
a weekly dose of teclistamab resulted in high response rates among adults with relapsed or refractory #multiplemyeloma, based on data from the majestec-1 study. #asco22 
MDedge: Keeping You Informed on What's Important in Medicine. Now part of the Medscape Professional Network.